儿童巴勒斯坦蝰蛇咬伤抗蛇毒血清治疗评价:两家大型三级儿童医院经验
该回顾性图表综述纳入2008年3月1日至2014年3月1日两家三级儿童医院收治的57例明确或疑似巴勒斯坦蝰蛇咬伤患儿,年龄1至17岁,中位9.5岁。55例(96.4%)有临床表现,37例出现快速进展性水肿和全身中毒体征。25例(42%)接受抗蛇毒血清,指征为中重度局部体征(19例)和全身体征(6例),均未出现过敏反应或血清病。1例因低血压和晕厥追加30 mL剂量后反应良好。作者结论认为50 mL剂量对儿童全身性和进行性局部表现有效且安全。
要点
- 57例患儿中55例(96.4%)有临床表现,37例表现为快速进展性水肿及全身中毒体征。
- 25例(42%)接受抗蛇毒血清,指征为中重度局部体征(19例)或全身体征(6例)。
- 接受抗蛇毒血清的25例均未发生不良反应、血清病或其他副作用。
- 2例发生骨筋膜室综合征并手术减压,均仅接受负荷剂量抗蛇毒血清、未给维持剂量。
- 1例因低血压和晕厥追加单次30 mL抗蛇毒血清后反应良好。
适用人群与场景
- 2008年3月1日至2014年3月1日入住Chaim Sheba医学中心和Kaplan医学中心的1至17岁儿童,具有巴勒斯坦蝰蛇咬伤的明确或 probable 体征。
处置流程与药物剂量
- 抗蛇毒血清为巴勒斯坦蝰蛇单价(马)免疫球蛋白G,固定50 mL剂量用于儿童。
- 抗蛇毒血清用药指征包括中重度局部体征(19例)和全身体征(6例)。
- 1例因低血压和晕厥追加单次30 mL抗蛇毒血清,反应良好。
红旗征与不能漏的情况
- 快速进展性水肿提示进行性局部中毒。
- 心动过速(20例)、呕吐(17例)、腹痛(11例)、低血压(6例)为全身中毒表现。
- 骨筋膜室综合征需手术减压(2例)。
- 血小板减少(1例)和轻度凝血病(3例)。
研究设计与关键结果
- 回顾性图表综述纳入57例患儿,年龄1至17岁,中位年龄9.5岁。
- 55例(96.4%)有临床表现:18例仅有轻微局部体征,37例有快速进展性水肿及全身中毒体征。
- 全身中毒体征包括心动过速20例、呕吐17例、腹痛11例、低血压6例。
- 25例(42%)接受抗蛇毒血清,指征为中重度局部体征19例和全身体征6例。
- 接受抗蛇毒血清者无不良反应、血清病或其他副作用;1例追加30 mL剂量后反应良好。
- 2例骨筋膜室综合征行手术减压,均仅接受负荷剂量抗蛇毒血清、未给维持剂量。
- 1例发生血小板减少,3例有轻度凝血病。
证据类型、等级与局限
- 证据类型:回顾性图表综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,儿童巴勒斯坦蝰蛇咬伤使用50 mL固定剂量抗蛇毒血清对全身性和进行性局部表现有效且安全。
- 接受抗蛇毒血清的25例均未出现不良反应,但原文未报告未用药组的不良反应比较。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Antivenom has been successfully used to treat systemic and progressive, local manifestations of envenomation inflicted by Vipera (V.) palaestinae, the most common venomous snake in Israel. The objective of this study was to evaluate the fixed dose V. palaestinae monovalent (equine) immunoglobulin G antivenom used in two pediatric emergency departments. In particular, we wanted to assess the need for repeated antivenom administration and the rate of adverse antivenom effects in children.
METHODS: A retrospective chart review was performed for all children admitted with definite or probable signs of V. palaestinae envenomation to Chaim Sheba Medical Center and Kaplan Medical Center between 1 March 2008 and 1 March 2014. Extracted data included: age, location of bite, time to hospital arrival, time to antivenom administration if indicated, outcomes, and complications of the envenomation and adverse effects to the antivenom.
RESULTS: 57 patients met inclusion criteria; they ranged from 1 to 17 years in age and median age was 9.5 years. Clinical manifestations were evident in 55 (96.4%) of victims: 18 presented with minimal local signs and 37 showed marked progressive, local features (rapidly progressing edema) and signs of systemic envenomation: tachycardia (20), vomiting (17), abdominal pain (11) and hypotension (6). Two patients developed compartment syndrome and underwent surgical decompression (both received only a loading dose of antivenom with no subsequent maintenance dose). One patient developed thrombocytopenia and three patients presented with mild coagulopathy. Antivenom was administered to 25 (42%) children. Indications for antivenom administration included moderate to severe local signs (19 patients) and systemic signs (6 patients). None of these patients developed adverse reactions, serum sickness, or other side effects to the antivenom. One patient received a single additional 30mL dose of antivenom, due to hypotension and syncope, with good response.
CONCLUSIONS: In children, 50 ml dosing of V. palaestinae antivenom is efficacious and safe for the treatment of systemic and progressive local manifestations of envenomation by V. palaestinae.
参考来源
- Pivko-Levy D, Munchnak I, Rimon A, et al. Evaluation of antivenom therapy for Vipera palaestinae bites in children: experience of two large, tertiary care pediatric hospitals. Clin Toxicol (Phila). 2017. PMID: 28103732. doi:10.1080/15563650.2016.1277233
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。